Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.

Golubovskaya VM, Berahovich R, Xu Q, Zhou H, Xu S, Guan J, Harto H, Li L, Wu L.

Front Biosci (Landmark Ed). 2018 Jun 1;23:2245-2254.

PMID:
29772559
2.

FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo.

Berahovich R, Xu S, Zhou H, Harto H, Xu Q, Garcia A, Liu F, Golubovskaya VM, Wu L.

Front Biosci (Landmark Ed). 2017 Jun 1;22:1644-1654.

PMID:
28410137
3.

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.

Zhang H, Shao H, Golubovskaya VM, Chen H, Cance W, Adjei AA, Dy GK.

Br J Cancer. 2016 Jul 12;115(2):203-11. doi: 10.1038/bjc.2016.190. Epub 2016 Jun 23.

4.

Synthesis and bioactivity of a Goralatide analog with antileukemic activity.

Li Z, Lebedyeva IO, Golubovskaya VM, Cance WG, Alamry KA, Faidallah HM, Dennis Hall C, Katritzky AR.

Bioorg Med Chem. 2015 Aug 1;23(15):5056-60. doi: 10.1016/j.bmc.2015.04.061. Epub 2015 May 14.

PMID:
26048023
5.

Defective apical extrusion signaling contributes to aggressive tumor hallmarks.

Gu Y, Shea J, Slattum G, Firpo MA, Alexander M, Mulvihill SJ, Golubovskaya VM, Rosenblatt J.

Elife. 2015 Jan 26;4:e04069. doi: 10.7554/eLife.04069.

6.

High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.

Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C, Cance WG.

BMC Cancer. 2014 Oct 17;14:769. doi: 10.1186/1471-2407-14-769.

7.
8.

The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.

Dy GK, Ylagan L, Pokharel S, Miller A, Brese E, Bshara W, Morrison C, Cance WG, Golubovskaya VM.

J Thorac Oncol. 2014 Sep;9(9):1278-84. doi: 10.1097/JTO.0000000000000248.

9.

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex.

Golubovskaya VM, Ho B, Conroy J, Liu S, Wang D, Cance WG.

Cancers (Basel). 2014 Jan 21;6(1):166-78. doi: 10.3390/cancers6010166.

10.

Focal adhesion kinase and cross-linked signaling in cancer.

Golubovskaya VM.

Anticancer Agents Med Chem. 2014 Jan;14(1):2. No abstract available.

PMID:
24410522
11.

Targeting FAK in human cancer: from finding to first clinical trials.

Golubovskaya VM.

Front Biosci (Landmark Ed). 2014 Jan 1;19:687-706. Review.

12.

Targeting the p53 pathway.

Golubovskaya VM, Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Epub 2013 Jul 30. Review.

13.

Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.

Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C, Cance WG.

BMC Cancer. 2013 Jul 11;13:342. doi: 10.1186/1471-2407-13-342.

14.

Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.

Heffler M, Golubovskaya VM, Dunn KM, Cance W.

Cancer Biol Ther. 2013 Aug;14(8):761-72. doi: 10.4161/cbt.25185. Epub 2013 Jun 3.

15.

MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.

Golubovskaya VM, Sumbler B, Ho B, Yemma M, Cance WG.

Anticancer Agents Med Chem. 2014 Jan;14(1):18-28.

16.

Focal adhesion kinase regulates expression of thioredoxin-interacting protein (TXNIP) in cancer cells.

Ho B, Huang G, Golubovskaya VM.

Anticancer Agents Med Chem. 2014 Jan;14(1):3-8.

17.

Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP, Cance WG.

Mol Cancer Ther. 2013 Feb;12(2):162-72. doi: 10.1158/1535-7163.MCT-12-0701. Epub 2012 Dec 12.

18.

Survival signaling through focal adhesion kinase in tumors.

Golubovskaya VM.

Anticancer Agents Med Chem. 2013 May;13(4):531. No abstract available.

PMID:
22934710
19.

FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.

Heffler M, Golubovskaya VM, Conroy J, Liu S, Wang D, Cance WG, Dunn KB.

Anticancer Agents Med Chem. 2013 May;13(4):584-94.

20.

FAK and Nanog cross talk with p53 in cancer stem cells.

Golubovskaya VM.

Anticancer Agents Med Chem. 2013 May;13(4):576-80. Review.

Supplemental Content

Loading ...
Support Center